Alnylam Pharmaceuticals Inc
ALNY328.160USD
-3.080-0.93%
Cierre 02/06, 16:00（ET）Cotizaciones retrasadas 15 min
43.25BCap. mercado
1010.56P/E TTM
Más Datos de Alnylam Pharmaceuticals Inc Compañía
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.
Información de Alnylam Pharmaceuticals Inc
Símbolo de cotizaciónALNY
Nombre de la empresaAlnylam Pharmaceuticals Inc
Fecha de salida a bolsaMay 28, 2004
Director ejecutivoGreenstreet (Yvonne L)
Número de empleados2230
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 28
Dirección675 W Kendall St
CiudadCAMBRIDGE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02142-1168
Teléfono16175518200
Sitio Webhttps://www.alnylam.com/
Símbolo de cotizaciónALNY
Fecha de salida a bolsaMay 28, 2004
Director ejecutivoGreenstreet (Yvonne L)
Ejecutivos de Alnylam Pharmaceuticals Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Yvonne L. Greenstreet, M.D.
Dr. Yvonne L. Greenstreet, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
78.82K
+9426.00%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
57.52K
+3413.00%
Mr. Tolga Tanguler
Mr. Tolga Tanguler
Chief Commercial Officer
Chief Commercial Officer
29.73K
+2290.00%
Dr. Dennis A. Ausiello, M.D.
Dr. Dennis A. Ausiello, M.D.
Independent Director
Independent Director
4.41K
--
Dr. Margaret A. Hamburg, M.D.
Dr. Margaret A. Hamburg, M.D.
Independent Director
Independent Director
911.00
+775.00%
Dr. Olivier Brandicourt, M.D.
Dr. Olivier Brandicourt, M.D.
Independent Director
Independent Director
775.00
+775.00%
Mr. Peter N. Kellogg
Mr. Peter N. Kellogg
Independent Director
Independent Director
775.00
+775.00%
Mr. David E. I. Pyott, CBE
Mr. David E. I. Pyott, CBE
Independent Director
Independent Director
--
--
Ms. Amy W. Schulman, J.D.
Ms. Amy W. Schulman, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Pushkal P. Garg, M.D.
Dr. Pushkal P. Garg, M.D.
Executive Vice President, Chief Research and Development Officer
Executive Vice President, Chief Research and Development Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Yvonne L. Greenstreet, M.D.
Dr. Yvonne L. Greenstreet, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
78.82K
+9426.00%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
57.52K
+3413.00%
Mr. Tolga Tanguler
Mr. Tolga Tanguler
Chief Commercial Officer
Chief Commercial Officer
29.73K
+2290.00%
Dr. Dennis A. Ausiello, M.D.
Dr. Dennis A. Ausiello, M.D.
Independent Director
Independent Director
4.41K
--
Dr. Margaret A. Hamburg, M.D.
Dr. Margaret A. Hamburg, M.D.
Independent Director
Independent Director
911.00
+775.00%
Dr. Olivier Brandicourt, M.D.
Dr. Olivier Brandicourt, M.D.
Independent Director
Independent Director
775.00
+775.00%
Desglose de ingresos
Divisa: USDActualizado: mar., 6 de ene
Divisa: USDActualizado: mar., 6 de ene
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
Por negocioUSD
Nombre
Ganancia
Proporción
AMVUTTRA
685.30M
54.87%
Regeneron Pharmaceuticals
326.60M
26.15%
GIVLAARI
73.87M
5.91%
OXLUMO
52.83M
4.23%
Other
48.80M
3.91%
Otro
61.62M
4.93%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
613.98M
49.16%
Net revenues from collaborations
351.74M
28.16%
Europe
172.67M
13.82%
Rest of World
64.43M
5.16%
Royalty revenue
46.20M
3.70%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
AMVUTTRA
685.30M
54.87%
Regeneron Pharmaceuticals
326.60M
26.15%
GIVLAARI
73.87M
5.91%
OXLUMO
52.83M
4.23%
Other
48.80M
3.91%
Otro
61.62M
4.93%
Estadísticas de accionistas
Actualizado: sáb., 7 de feb
Actualizado: sáb., 7 de feb
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Capital World Investors
12.44%
Fidelity Management & Research Company LLC
12.04%
The Vanguard Group, Inc.
10.21%
Capital Research Global Investors
5.47%
BlackRock Institutional Trust Company, N.A.
4.98%
Otro
54.86%
Accionistas
Accionistas
Proporción
Capital World Investors
12.44%
Fidelity Management & Research Company LLC
12.04%
The Vanguard Group, Inc.
10.21%
Capital Research Global Investors
5.47%
BlackRock Institutional Trust Company, N.A.
4.98%
Otro
54.86%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
69.40%
Investment Advisor/Hedge Fund
23.27%
Hedge Fund
3.81%
Research Firm
2.50%
Sovereign Wealth Fund
1.70%
Pension Fund
1.30%
Bank and Trust
1.26%
Individual Investor
0.43%
Private Equity
0.23%
Participación institucional
Actualizado: lun., 8 de dic
Actualizado: lun., 8 de dic
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
1441
132.38M
102.07%
-8.88K
2025Q3
1468
132.43M
102.39%
+2.53M
2025Q2
1335
129.81M
101.55%
+2.82M
2025Q1
1292
127.17M
99.72%
-2.77M
2024Q4
1248
125.34M
101.87%
-989.05K
2024Q3
1210
126.51M
99.20%
+3.13M
2024Q2
1165
122.70M
94.98%
+5.27M
2024Q1
1152
117.38M
97.56%
-6.00M
2023Q4
1149
120.10M
100.10%
-712.55K
2023Q3
1103
121.13M
101.32%
-503.11K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Capital World Investors
16.43M
12.44%
-370.75K
-2.21%
Sep 30, 2025
Fidelity Management & Research Company LLC
15.91M
12.04%
+854.66K
+5.68%
Sep 30, 2025
The Vanguard Group, Inc.
13.51M
10.22%
+267.08K
+2.02%
Sep 30, 2025
Capital Research Global Investors
7.22M
5.47%
+31.18K
+0.43%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
6.59M
4.98%
+52.87K
+0.81%
Sep 30, 2025
JP Morgan Asset Management
3.87M
2.93%
+2.07M
+115.83%
Sep 30, 2025
State Street Investment Management (US)
3.08M
2.33%
-91.63K
-2.89%
Sep 30, 2025
Baillie Gifford & Co.
2.79M
2.11%
-242.53K
-8.00%
Sep 30, 2025
Geode Capital Management, L.L.C.
2.50M
1.89%
+100.47K
+4.19%
Sep 30, 2025
Ver más
ETFs relacionados
Actualizado: mar., 2 de dic
Actualizado: mar., 2 de dic
Nombre
Proporción
Global X Genomics & Biotechnology ETF
6.48%
ProShares Ultra Nasdaq Biotechnology
5.81%
Invesco Nasdaq Biotechnology ETF
5.77%
Franklin Genomic Advancements ETF
5.35%
iShares Biotechnology ETF
5.07%
VanEck Biotech ETF
4.56%
American Century Focused Dynamic Growth ETF
3.76%
Goldman Sachs Future Health Care Equity ETF
3.42%
First Trust NYSE Arca Biotechnology Index Fund
3.33%
Invesco NASDAQ Next Gen 100 ETF
3.28%
Ver más
Global X Genomics & Biotechnology ETF
Proporción6.48%
ProShares Ultra Nasdaq Biotechnology
Proporción5.81%
Invesco Nasdaq Biotechnology ETF
Proporción5.77%
Franklin Genomic Advancements ETF
Proporción5.35%
iShares Biotechnology ETF
Proporción5.07%
VanEck Biotech ETF
Proporción4.56%
American Century Focused Dynamic Growth ETF
Proporción3.76%
Goldman Sachs Future Health Care Equity ETF
Proporción3.42%
First Trust NYSE Arca Biotechnology Index Fund
Proporción3.33%
Invesco NASDAQ Next Gen 100 ETF
Proporción3.28%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
